Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 759% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 68.6% with 32.6% net margin
- Revenue growing at 45% annually
Eli Lilly and Company Common Stock (LLY) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $1.1 trillion . Key value metrics: P/E ratio 49.2, P/B ratio 33.73, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Eli Lilly and Company Common Stock — Fundamental Analysis Summary
Eli Lilly and Company Common Stock (LLY) is currently trading 759% above its Graham Number of $130.14, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 49.2x.
On financial health, LLY shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 68.6% (sector average: -20.6%), and elevated leverage with a debt-to-equity ratio of 1.39.
StockPik's composite Value Score for LLY is 51/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
LLY shows revenue growing at 45% year-over-year, with earnings growing at 95%.
LLY pays a modest dividend yield of 0.6%.